Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard; Wanner, Christoph; M. Lachin, John; Fitchett, David; Bluhmki, Erich; Hantel, Stefan; Mattheus, Michaela; Devins, Theresa; Erik Johansen, Odd; J. Woerle, Hans; C. Broedl, Uli; E. Inzucchi, Silvio

doi:10.1056/nejmoa1504720

Public

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Published in New England Journal of Medicine • Sep 17, 2015

Authors:

Bernard Zinman

Christoph Wanner

John M. Lachin

Abstract

BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 ...

Subject

Empagliflozin

Medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!